PURPOSE OF REVIEW: Hematopoietic stem cell and umbilical cord blood transplantation can be a life-saving procedure for many patients with myeloid malignancies. The posttransplant period, however, can be complicated by graft failure and disease relapse, prompting the need for further therapy. Herein, we review and examine the data of second allogeneic stem cell transplant after autologous, allogeneic and umbilical cord blood transplantation. RECENT FINDINGS: Although large, prospective, multicenter trials are lacking, certain factors such as younger patient age, lower disease burden and a longer interval between first transplantation and relapse appear to portend a better prognosis for second transplant. SUMMARY: Currently, only a selected group of patients without important comorbidities should be considered for second allogeneic transplantation. Strategies such as new immunosuppressive agents, antileukemia monoclonal antibodies, graft modification and use of molecularly targeted therapy are needed to decrease the morbidity and increase the efficacy of transplantation.
PURPOSE OF REVIEW: Hematopoietic stem cell and umbilical cord blood transplantation can be a life-saving procedure for many patients with myeloid malignancies. The posttransplant period, however, can be complicated by graft failure and disease relapse, prompting the need for further therapy. Herein, we review and examine the data of second allogeneic stem cell transplant after autologous, allogeneic and umbilical cord blood transplantation. RECENT FINDINGS: Although large, prospective, multicenter trials are lacking, certain factors such as younger patient age, lower disease burden and a longer interval between first transplantation and relapse appear to portend a better prognosis for second transplant. SUMMARY: Currently, only a selected group of patients without important comorbidities should be considered for second allogeneic transplantation. Strategies such as new immunosuppressive agents, antileukemia monoclonal antibodies, graft modification and use of molecularly targeted therapy are needed to decrease the morbidity and increase the efficacy of transplantation.
Authors: Uwe Platzbecker; Marc Binder; Christoph Schmid; Claudia Rutt; Gerhard Ehninger; Martin Bornhäuser Journal: Haematologica Date: 2008-06-02 Impact factor: 9.941
Authors: B J Byrne; M Horwitz; G D Long; C Gasparetto; K M Sullivan; J Chute; N J Chao; D A Rizzieri Journal: Bone Marrow Transplant Date: 2007-11-05 Impact factor: 5.483
Authors: Joseph H Chewning; Hugo Castro-Malaspina; Ann Jakubowski; Nancy A Kernan; Esperanza B Papadopoulos; Trudy N Small; Glenn Heller; Katharine C Hsu; Miguel A Perales; Marcel R M van den Brink; James W Young; Susan E Prockop; Nancy H Collins; Richard J O'Reilly; Farid Boulad Journal: Biol Blood Marrow Transplant Date: 2007-09-07 Impact factor: 5.742
Authors: Peter Lang; Ingo Mueller; Johann Greil; Peter Bader; Michael Schumm; Matthias Pfeiffer; Walter Hoelle; Thomas Klingebiel; Frank Heinzelmann; Claus Belka; Paul G Schlegel; Bernhard Kremens; Wilhelm Woessmann; Rupert Handgretinger Journal: Blood Cells Mol Dis Date: 2007-09-19 Impact factor: 3.039
Authors: Frank Heinzelmann; Peter J Lang; Hellmut Ottinger; Christoph Faul; Wolfgang Bethge; Rupert Handgretinger; Michael Bamberg; Claus Belka Journal: Int J Radiat Oncol Biol Phys Date: 2007-09-14 Impact factor: 7.038
Authors: D A Pollyea; A S Artz; W Stock; C Daugherty; L Godley; O M Odenike; E Rich; S M Smith; T Zimmerman; Y Zhang; D Huo; R Larson; K van Besien Journal: Bone Marrow Transplant Date: 2007-09-10 Impact factor: 5.483
Authors: Marcos de Lima; Sergio Giralt; Peter F Thall; Leandro de Padua Silva; Roy B Jones; Krishna Komanduri; Thomas M Braun; Hoang Q Nguyen; Richard Champlin; Guillermo Garcia-Manero Journal: Cancer Date: 2010-07-29 Impact factor: 6.860
Authors: Ann Dahlberg; Wendy Leisenring; Marie Bleakley; Soheil Meshinchi; K Scott Baker; Corinne Summers; Brandon Hadland; Colleen Delaney; Kanwaldeep Mallhi; Lauri Burroughs; Paul Carpenter; Ann Woolfrey Journal: Bone Marrow Transplant Date: 2019-01-22 Impact factor: 5.483
Authors: Christine N Duncan; Navneet S Majhail; Ruta Brazauskas; Zhiwei Wang; Jean-Yves Cahn; Haydar A Frangoul; Robert J Hayashi; Jack W Hsu; Rammurti T Kamble; Kimberly A Kasow; Nandita Khera; Hillard M Lazarus; Alison W Loren; David I Marks; Richard T Maziarz; Paulette Mehta; Kasiani C Myers; Maxim Norkin; Joseph A Pidala; David L Porter; Vijay Reddy; Wael Saber; Bipin N Savani; Harry C Schouten; Amir Steinberg; Donna A Wall; Anne B Warwick; William A Wood; Lolie C Yu; David A Jacobsohn; Mohamed L Sorror Journal: Biol Blood Marrow Transplant Date: 2014-10-12 Impact factor: 5.742
Authors: Troy C Lund; Jessica Liegel; Nelli Bejanyan; Paul J Orchard; Qing Cao; Jakub Tolar; Claudio Brunstein; John E Wagner; Michael R Verneris; Daniel Weisdorf Journal: Am J Hematol Date: 2015-10 Impact factor: 10.047
Authors: Jeffrey Schriber; Manza-A Agovi; Vincent Ho; Karen K Ballen; Andrea Bacigalupo; Hillard M Lazarus; Christopher N Bredeson; Vikas Gupta; Richard T Maziarz; Gregory A Hale; Mark R Litzow; Brent Logan; Martin Bornhauser; Roger H Giller; Luis Isola; David I Marks; J Douglas Rizzo; Marcelo C Pasquini Journal: Biol Blood Marrow Transplant Date: 2010-02-19 Impact factor: 5.742
Authors: David L Porter; Edwin P Alyea; Joseph H Antin; Marcos DeLima; Eli Estey; J H Frederik Falkenburg; Nancy Hardy; Nicolaus Kroeger; Jose Leis; John Levine; David G Maloney; Karl Peggs; Jacob M Rowe; Alan S Wayne; Sergio Giralt; Michael R Bishop; Koen van Besien Journal: Biol Blood Marrow Transplant Date: 2010-08-10 Impact factor: 5.742
Authors: T Ruutu; L C de Wreede; A van Biezen; R Brand; M Mohty; P Dreger; R Duarte; C Peters; L Garderet; S Schönland; A Gratwohl; D Niederwieser; T de Witte; N Kröger Journal: Bone Marrow Transplant Date: 2015-09-14 Impact factor: 5.483
Authors: Nandita Khera; Barry Storer; Brenda M Sandmaier; Michael K Chapko; Stephanie J Lee Journal: Transplantation Date: 2013-07-15 Impact factor: 4.939